Purpose of review Acute kidney injury (AKI) occurrence in critically ill patients is common and is associated with a substantial increase in morbidity and mortality. The scope of this review is to summarize the most recent evidencebased knowledge for prevention of AKI.
INTRODUCTION
Acute kidney injury (AKI) is a serious complication in ICU patients accounting for 18-47% of all hospital-acquired AKI [1] , augmenting hospitalization cost [2] , and increasing mortality [3] . In patients admitted to ICU, AKI is an independent risk factor for mortality at 6 months follow-up and, even more interestingly, just the occurrence of AKI, independently of its evolution, affects outcome [4] .
Major causes of AKI in ICU include renal hypoperfusion, sepsis/systemic inflammatory response syndrome (SIRS), and direct nephrotoxicity, although in most cases pathogenesis is multifactorial [5, 6] , involving also not modifiable factors (i.e. age, comorbidities, severity of illness). Due to this reason it is not surprising that a systematic review did not find any reliable evidence to suggest that a single treatment (i.e. dopamine, diuretics, calciumchannel blockers, or angiotensin-converting enzyme inhibitors) can protect the kidneys [7] . Recent recommendations for the protection and prevention of AKI in ICU patients are all 'negative' 1A recommendations (strong recommendation with a high degree of evidence), and the few old 'positive' clinical indications have been downgraded to suggestions with low grade of evidence [8, 9] . Similarly, the most recent and updated guidelines (Kidney Disease: Improving Global Outcomes -KIDGO) about four major topic areas of interest for AKI, including definition and classification, prevention, pharmacologic treatment, and renal replacement therapy (RRT), have failed to identify single evidence-based recommendations for prevention and treatment of AKI [10 [11 && ,12] that evaluation, prevention, and management of AKI should be guided by a multimodal approach, consisting of clinical algorithms, taking into account all the above mentioned factors, in order to minimize renal insult and protect kidneys.
The scope of this review is to summarize the most recent evidence-based knowledge for prevention of AKI.
ACUTE KIDNEY INJURY DEFINITION
First of all, in order to prevent AKI, it is mandatory to know what we are talking about, and, therefore, a key factor is how to define it. KIDGO guidelines [10 && ] propose to define AKI on the basis of The Acute Kidney Injury Network criteria [13] , and to stage it for severity by including only three levels of injury, ranging from small increases in creatinine (Cr) (1.5-1.9 times baseline, or >0.3 mg/dl) to the need of RRT.
In KIDGO guidelines no mention at all has been made for early biomarkers' capability to identify an ongoing kidney insult before Cr variation. The most promising is neutrophil gelatinase-associated lipocalin (NGAL). In a large multicenter analysis [14 && ] a positive NGAL identified approximately 40% more AKI cases than Cr alone and suggested that these patients were at greater risk of death compared with control individuals. Very recent trials [15
proposed that a single NGAL measurement at ICU admission may predict later-onset AKI as well as ICU mortality, both alone or in combination with other AKI biomarkers.
PREVENTIVE AND TREATMENT STRATEGIES
There are numerous, often co-existent, physiologic and clinical insults occurring in critically ill patients that have the potential to negatively impact kidney function. All these factors should be prevented or treated (Fig. 1 ).
Optimize volume status and perfusion pressure
Both relative and overt hypovolemia are significant risk factors for the development of AKI. Consequently, timely fluid administration should be effective by restoring circulating volume, although it will not always be sufficient to prevent renal failure. Moreover, it is often difficult for clinicians to assess the amount of fluids to administer to a given patient. On one hand, failure to prescribe adequate intravenous fluid can place a patient at risk of hypovolemia; on the other hand, excessive fluid infusion may promote third space loss and fluid overload. At the moment, an individualized, timely, protocol-based fluid 'replacement' therapy, aimed to physiologic flow-related end-points with appropriate monitoring [17] , is a rational choice. The question of fluid infusion regards not only the amount of fluids, but also their quality since colloids, whereas maintaining the plasma volume more efficiently than crystalloids, may affect renal function, and the renal effects of hyperoncotic colloid solutions appear to be colloid-specific. Whereas hyperoncotic albumin seems to decrease the odds of AKI, hyperoncotic starch increases those odds by 92% [odds ratio (OR) 1.92; confidence interval (CI) 1.31-2.81; P ¼ 0.0008] [18] . A Cochrane review has suggested that hydroxyethyl starch (HES) carries an increased risk of AKI in septic patients compared to nonseptic surgical and trauma patients [19] , and the mean colloid cumulative dose has been shown to be associated with AKI [20] . A subsequent meta-analysis [21 && ], analyzing whether the exclusion of some retracted trials had altered the balance of evidence, has not clarified this issue, due to insufficient quantity and quality of data reporting AKI. 
KEY POINTS
Acute kidney injury (AKI) prevention should be guided by a step-wise, multimodal clinical algorithm based on protocolized hemodynamic optimization, associated with strategies aimed to minimize renal injury by nephrotoxic drugs and other systemic factors.
Although targets and monitoring can vary, depending on the presence of organ dysfunction and/or heart failure, avoiding hypotension and optimizing oxygen delivery, by careful fluid management, vasopressors, inotropic agents, and blood products when indicated, are key elements of hemodynamic optimization.
An individualized, fluid 'replacement' therapy, aimed to physiologic flow-related end-points is warranted in patients at risk of AKI, possibly avoiding 6% hydroxyethyl starch (HES) 130/0.4 or gelatin.
Strict glycemic control (blood glucose 80-110 mg/dl) is not advisable to prevent AKI and a target below 150 mg/dl should be adopted.
Appropriate drug dosing based on the knowledge of altered pharmacokinetics in ICU patients and vigilant monitoring of drug efficacy and toxicity are essential to prevent drug-induced AKI.
gelatin in patients with risk of AKI, considering the evidence for renal effects as having moderate and low quality, respectively. Similarly, KIDGO guidelines [10 && ] suggest using crystalloids rather than colloids for expansion of intravascular volume in patients at risk or with AKI, in absence of hemorrhagic shock (degree of recommendation 2B, i.e. suggestion of moderate quality of evidence). This evidence has been strengthened by the results of the most recent randomized controlled trial (RCT) on the topic showing that patients with severe sepsis receiving fluid resuscitation with HES 130/0.42 had an increased risk of death at day 90 and were more likely to require RRT, as compared with those receiving Ringer's acetate [23 && ]. Fluid loading, no matter how performed, is the starting point of all protocols of perioperative hemodynamic optimization, aiming to achieve adequate oxygen delivery to face an increase in oxygen demand and to prevent organ failure [24] . A recent meta-analysis of studies on this issue by Brienza et al. [25] concluded that protocolized therapies (regardless of the protocol) with specific physiological hemodynamic goals can significantly reduce postoperative AKI. Unfortunately, most studies have varied in their approaches to both the timing and the modalities of interventions, the targets, the monitoring tools, and the type of patients enrolled [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , and it can only be concluded that adoption of hemodynamic protocols for AKI prevention in the setting of high-risk surgery appears to be superior to no protocol at all, although no specific hemodynamic strategy can be recommended (Table 1) . Despite these limitations, however, a strategy of goal-directed therapies, based on avoiding hypotension, and optimizing oxygen delivery, including careful fluid management, vasopressors when indicated, and inotropic agents and blood products if needed, is the only evidence-based intervention able to reduce kidney injury in postoperative patients.
In order to obtain these targets specific hemodynamic monitoring is mandatory. The choice of perioperative hemodynamic monitoring for hemodynamic optimization should depend on surgeryrelated and patient-related risk factors. A modular stepwise monitoring concept [46] may provide a track for stratification of monitoring levels and targets for therapy. Conventional invasive hemodynamic monitoring may be appropriate when the patient presents with predefined values of hemodynamics (heart rate 100 beats/min, mean arterial pressure >65 mmHg, central venous pressure 8-12 mmHg), and adequate organ function (lactate 1-2 mmol/l, urine output 1 ml/kg/h) and oxygen transport (central venous oxygen saturationScVO 2 ->70% and hemoglobin 8-10 g/dl) parameters. A shift to higher monitoring level may be necessary when the patient fails to improve organ function following an early fluid loading with , a global end-diastolic volume index in the 600-800 ml/m 2 range, as well as predictors of fluid responsiveness in the normal range. In case of left/right heart failure and/or pulmonary hypertension, a pulmonary artery catheter for CI monitoring in association with pulmonary arterial occlusion pressure (12-15 mmHg), mixed venous oxygen saturation (>65%), and continuous right-ventricular end-diastolic volume (110-130 ml/m 2 ) may be a rational choice.
As mentioned above, avoiding hypotension is a mainstay of hemodynamic optimization. In patients with persistent hypotension despite volume loading, vasopressors are often employed to increase mean arterial pressure (MAP) with the goal of ensuring optimal renal perfusion. In septic patients norepinephrine has been traditionally used to increase blood pressure with improvement of Cr clearance [47] . A RCT comparing dopamine with norepinephrine as initial vasopressor in septic shock showed no significant differences between groups with regard to renal function or mortality, even if the use of norepinephrine was associated with less incidence of arrhythmias [48] . Results of the Vasopressin and Septic Shock Trial (VASST) [49] suggest that, compared with norepinephrine, vasopressin may offer some advantage only in patients with less severe septic shock. The use of norepinephrine to improve renal oxygen delivery and renal oxygenation has been tested in another kind of vasodilatory shock (i.e. postcardiac surgery), aiming at different targets of MAP (between 60 and 90 mmHg) [50 & ]. The main conclusion of this study was that restoration of MAP from 60 to 75 mmHg improves renal oxygen delivery, but no further benefit is obtained at higher levels of MAP. This pressure-dependent renal oxygenation at levels below 75 mmHg reflects a more or less exhausted renal autoregulatory reserve. In 217 patients with sustained hypotension the evolution of MAP during the first 24 h has been compared between patients who developed AKI 72 h after inclusion and patients who did not [51
Results of the study showed that patients with initial hypotension-induced renal impairment may need higher levels of MAP (72-82 mmHg) than the usually recommended 65 mmHg.
Diuretics
Diuretics are frequently used in patients at risk of AKI, and in the management of those who develop AKI, to convert oliguric to nonoliguric AKI, and to control fluid balance. There is, however, no evidence from available literature that diuretics can protect the kidneys, and their use to prevent or treat AKI is discouraged [7] . The only recent evidence of benefit deriving from furosemide use comes from a post-hoc analysis [52 & ] showing that a positive fluid balance after in-hospital AKI carries a strong and consistent association with mortality, whereas high diuretic dose after AKI onset has a protective effect on survival. Future RCTs on diuretic administration and fluid balance in critically ill patients with AKI are clearly warranted to clarify this issue.
Metabolic control
In 2001 an RCT in surgical ICU patients compared tight blood glucose control with insulin (blood glucose 80-110 mg/dl) versus standard care (blood glucose of 150-160 mg/dl), showing an improved survival rate and a 41% reduction in AKI requiring RRT [53] . These positive findings have been questioned by the NICE-SUGAR trial [54] , including surgical patients, but not limited to them, showing that a blood glucose target of 180 mg/dl or less resulted in lower mortality than an intensive target of 81-108 mg/dl, with no effect on RRT. A recent meta-analysis [55] , including also the NICE-SUGAR trial, has tried to put the controversial results in a different perspective analyzing subgroups of mixed, medical, and surgical ICU patients, concluding that a beneficial effect, if any, on mortality of this therapy may be restricted only to patients in surgical ICU. Considering the ratio between the benefits of avoiding hyperglycemia and the harm of hypoglycemia, recent guidelines (KIDGO [10 && ]) suggest that the average blood glucose should not exceed 150 mg/dl and that insulin therapy should not be used to lower glycemia to less than 110 mg/dl (2C, i.e. suggestion with low quality of evidence). Moreover, these targets may not benefit all patients. Recent findings suggest that patients with pre-existing hyperglycemia might do worse if rapid and substantial lowering of their blood glucose levels occurs during an acute illness [56 & ].
Intra-abdominal hypertension
Oliguria and renal dysfunction are among the earliest signs of increasing intra-abdominal pressure (IAP). 'Third space' losses from compromised bowel capillary endothelium by reperfusion (such as after hemorrhagic shock) or by inflammatory mediators injury (such as during SIRS or sepsis or major surgery) associated with a positive fluid balance might lead to gut edema and IAH [57] . The compression of the intra-abdominal and intra-thoracic blood vessels compromises micro-vascular blood flow, leading to intestinal and mesenteric vascular venous congestion, ischemia, and edema [58 & ]. This results in a fluid overload condition, leading to a vicious cycle that perpetuates IAH itself and renal injury [57] . Therefore, when IAH is present in an oliguric patient, IAP should be carefully monitored and crystalloid use should be avoided or limited. Specific medical treatments up to surgical options should be considered to decrease IAP [59] . Recently, an intensivist-performed bedside drainage (percutaneous catheter decompression) has been demonstrated to be an effective and less invasive technique for treating patients with IAH when free intraperitoneal fluid or blood is present as determined by bedside ultrasonography [60] .
Drugs
The contribution of treatment-related renal injury as a preventable cause of AKI is frequently underestimated. In severe AKI, nephrotoxic drugs are contributing factors of up to 19-25% of cases [1, 61] . In ICU patients, drug-induced AKI is mediated by inherent drug nephrotoxic potential, and by both significant underlying chronic disease states and acute, lifethreatening illnesses, impairing drugs pharmacokinetics and leading to overdosing.
Drugs may exert a direct nephrotoxic effect by several mechanisms. Most commonly, renally excreted drugs, such as aminoglycosides, vancomycin, colistin, or conventional formulation of amphotericin B, exert a direct toxic effect on renal tubules, inducing cellular injury and death with acute tubular necrosis. Known & ]. Moreover, whereas acyclovir or sulfa-based medications are administered, fluid infusion and prolonged infusion times are useful in order to prevent crystal-induced tubular injury and luminal obstruction. Less frequently, drugs (antimicrobials, antiulcer agents, anticonvulsants, diuretics, and host for other medications) induce renal interstitium flogosis with acute interstitial nephritis (AIN), which is difficult to ascertain. In these cases, a high index of suspicion for druginduced AIN and a confirmatory kidney biopsy are required [65 & ].
Commonly used drugs (radiocontrast dye, NSAIDs, renin-angiotensin-aldosterone system blockers, high-dose systemic vasoconstrictors, calcineurin inhibitors) may also be indirectly nephrotoxic by impairing intra-renal blood flow, making the kidneys vulnerable to ischemia and injury in low-flow states such as sepsis, volume depletion, major surgery, trauma, and acute decompensated heart failure [66] . In critically ill patients, contrastinduced (CI)-AKI is associated with a three-fold increase in mortality, with hypotensive or on vasopressor therapy chronic renal disease patients mostly at risk [67 & ]. Moreover, the occurrence of CI-AKI is largely determined by preprocedural renal function, volume of radiocontrast agent given, and concomitant nephrotoxic agents. Thus, volume expansion with isotonic sodium chloride or sodium bicarbonate solutions, low or iso-osmolar contrast medium at a volume as low as possible, along with withholding or substitution of nephrotoxic drugs before and immediately after contrast medium administration have been recommended in patients at increased risk for CI-AKI [9,10 && ] . With the possible exception of high-dose N-acetylcysteine, no treatment has been unequivocally proven efficient in reducing CI-AKI risk [9,10 && ]. Another major contributor to drug-induced toxicity is impaired drugs pharmacokinetics which frequently occurs in critically ill and major surgical patients. Drug distribution, metabolism, and excretion are significantly altered due primarily to changes in blood delivery, tissue permeability, microenvironment pH, drug characteristics (lipid solubility, pKa, and protein binding), and hepatic and renal functions. Drug therapy that does not account for this will lead to over-dosing and endorgan toxicity, and pharmacokinetic changes, individualized to each patient, must be factored into drug-dosing to maximize efficacy and minimize renal toxicity [65 & ]. In view of these issues, it is crucial that clinicians use appropriate drug-dosing based on the knowledge of altered pharmacokinetics, vigilant monitoring of drug efficacy and toxicity, recognition of drugs with nephrotoxic potential, and early identification of drug-induced AKI when it develops. A very recent study [68 && ] confirms this approach, demonstrating that with the aim to treating life-threatening gram-negative bacterial infections, high-dose, extended-interval dosing strategy of colistin, with ongoing adaption to renal function, can be used with satisfactory efficacy and relatively low nephrotoxicity. Table 2 displays primary pathogenetic mechanism, clinical characteristics, risk factors, and preventive strategies in high-risk patients, and management of druginduced AKI in surgical and critically ill patients.
CONCLUSION
Improving the renal outcome is highly desirable from a clinical standpoint and considering resources allocation. The most recent and updated guidelines (KIDGO) have failed to identify single evidence-based recommendations for prevention and treatment of AKI. However, a strategy consisting of protocolized hemodynamic optimization, associated with stepwise, multimodal kidney approach, aimed to minimize renal injury by nephrotoxic drugs and systemic factors, instead of single treatments, should be the cornerstone of AKI prevention.
